1. Home
  2. ARMP vs HNNA Comparison

ARMP vs HNNA Comparison

Compare ARMP & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARMP
  • HNNA
  • Stock Information
  • Founded
  • ARMP N/A
  • HNNA 1989
  • Country
  • ARMP United States
  • HNNA United States
  • Employees
  • ARMP N/A
  • HNNA N/A
  • Industry
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • HNNA Investment Managers
  • Sector
  • ARMP Health Care
  • HNNA Finance
  • Exchange
  • ARMP Nasdaq
  • HNNA Nasdaq
  • Market Cap
  • ARMP 92.4M
  • HNNA 98.7M
  • IPO Year
  • ARMP N/A
  • HNNA N/A
  • Fundamental
  • Price
  • ARMP $2.61
  • HNNA $11.18
  • Analyst Decision
  • ARMP Strong Buy
  • HNNA
  • Analyst Count
  • ARMP 1
  • HNNA 0
  • Target Price
  • ARMP $9.00
  • HNNA N/A
  • AVG Volume (30 Days)
  • ARMP 9.3K
  • HNNA 11.6K
  • Earning Date
  • ARMP 08-12-2025
  • HNNA 08-06-2025
  • Dividend Yield
  • ARMP N/A
  • HNNA 5.05%
  • EPS Growth
  • ARMP N/A
  • HNNA 56.56
  • EPS
  • ARMP N/A
  • HNNA 1.25
  • Revenue
  • ARMP $6,868,000.00
  • HNNA $35,816,000.00
  • Revenue This Year
  • ARMP $8.43
  • HNNA N/A
  • Revenue Next Year
  • ARMP N/A
  • HNNA N/A
  • P/E Ratio
  • ARMP N/A
  • HNNA $8.82
  • Revenue Growth
  • ARMP 84.67
  • HNNA 32.04
  • 52 Week Low
  • ARMP $0.90
  • HNNA $8.43
  • 52 Week High
  • ARMP $2.96
  • HNNA $13.88
  • Technical
  • Relative Strength Index (RSI)
  • ARMP 58.67
  • HNNA 42.52
  • Support Level
  • ARMP $2.43
  • HNNA $10.49
  • Resistance Level
  • ARMP $2.72
  • HNNA $11.31
  • Average True Range (ATR)
  • ARMP 0.18
  • HNNA 0.64
  • MACD
  • ARMP -0.01
  • HNNA -0.04
  • Stochastic Oscillator
  • ARMP 70.08
  • HNNA 31.15

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About HNNA Hennessy Advisors Inc.

Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.

Share on Social Networks: